Vector Remote Care: Study Finds Remote Cardiac Monitoring Programs Significantly More Successful When Patients, Not Devices, Are Primary Focus

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Vector Remote Care today announced the results of a survey on the adoption of remote cardiac monitoring solutions and their impact on managing heart disease in the U.S.

The findings reveal that remote cardiac monitoring (RCM) programs that focus on just remote device data management are missing out on both clinical and financial benefits. In comparison, cardiology practices taking a patient-centric approach focused on data and patient compliance, report improved clinical and financial outcomes.

The survey of over 110 respondents with various roles within a cardiology practice shows nearly 75 percent of respondents believe improving patient outcomes is the first or second priority for their monitoring program.

Nevertheless, narrowing the scope to physician respondents, 43 percent revealed that only 20 percent or less of their heart disease patients are connected (and result in billable reports), which indicates a large margin of missed opportunities for improved clinical and financial outcomes. Despite less-than-optimal connection rates, a strong majority of total respondents—68.75 percent— rate their program as good or excellent.

According to Kristin Stitt, DNP, APRN, Chief Clinical Officer at Vector, “These numbers are not surprising, as RCM is still relatively new. Strong satisfaction with a program that has low connection rates indicates that many practices focus on getting the devices up and running, but are not fully aware of what is possible when you design your program around patient care.”

While 93.52 percent of respondents are doing remote monitoring for rhythm management, about one-third of those practices have less than 60 percent of their patients regularly connected. In addition, fewer than 68 percent of respondents are monitoring for heart failure, and fewer than 19 percent are monitoring for hypertension.

Programs with 80-100 percent of their patients connected are most successful at gathering the revenue needed to cover program costs. Practices with less than 60 percent of patients routinely connected for billable reports clearly see covering costs as a significant challenge.

Electrophysiologist Christopher Porterfield, MD, states, “There are hundreds to thousands of stories where remote monitoring has made it easier to care for patients and, in many cases, to save lives.” Dr. Porterfield assisted with survey development and analysis of the responses.

Additional findings show practices struggle to keep patients engaged in their care, placing a strain on staff and making it impossible for clinical and financial benefits to be fully realized. All respondents view keeping patients connected, reviewing alerts, and preparing reports as their biggest challenges, but practices’ staff doing the monitoring are the most burdened.

Respondents partnering with a third-party vendor cite improved satisfaction in being able to offload time-consuming administrative work. Third party success in enrolling patients, keeping them connected, and collecting appropriate revenue is likely due to a combination of clear goals, streamlined workflows, technology, and support services that ease burdens listed above.



Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles